# A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo

> **NCT07647237** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 116 (estimated)

## Conditions studied

- Vitiligo

## Interventions

- **BIOLOGICAL:** GR2301 injection
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07647237
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2028-06
- **Final completion:** 2028-12
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647237, "A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*